Journal article icon

Journal article

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

Abstract:

OBJECTIVES: To address the structural issues relating to mortality and quality of life (QoL) effects and to identify data on the general pattern of QoL of rheumatoid arthritis (RA) patients through a restructured and enhanced version of the Birmingham Preliminary Model (BPM). DATA SOURCES: Electronic databases and a postal survey of current UK rheumatological practice. REVIEW METHODS: The focus for this report was to evaluate two new drugs, etanercept and infliximab [antibodies against tumour...

Expand abstract

Actions


Authors


Jobanputra, P More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Primary Care Health Sciences, PHC-EBM
Journal:
Health technology assessment (Winchester, England)
Volume:
8
Issue:
11
Pages:
iii-91
Publication date:
2004-03-05
EISSN:
2046-4924
ISSN:
1366-5278
URN:
uuid:e26c9477-526f-4198-aa7f-39b3b8473460
Source identifiers:
116186
Local pid:
pubs:116186

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP